Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis
JournalPLoS neglected tropical diseases
PublisherPublic Library of Science
MetadataShow full item record
AbstractBacillus anthracis and Yersinia pestis are zoonotic bacteria capable of causing severe and sometimes fatal infections in animals and humans. Although considered as diseases of antiquity in industrialized countries due to animal and public health improvements, they remain endemic in vast regions of the world disproportionally affecting the poor. These pathogens also remain a serious threat if deployed in biological warfare. A single vaccine capable of stimulating rapid protection against both pathogens would be an extremely advantageous public health tool. We produced multiple-antigen fusion proteins (MaF1 and MaF2) containing protective regions from B. anthracis protective antigen (PA) and lethal factor (LF), and from Y. pestis V antigen (LcrV) and fraction 1 (F1) capsule. The MaF2 sequence was also expressed from a plasmid construct (pDNA-MaF2). Immunogenicity and protective efficacy were investigated in mice following homologous and heterologous prime-boost immunization. Antibody responses were determined by ELISA and anthrax toxin neutralization assay. Vaccine efficacy was determined against lethal challenge with either anthrax toxin or Y. pestis. Both constructs elicited LcrV and LF-specific serum IgG, and MaF2 elicited toxin-neutralizing antibodies. Immunizations with MaF2 conferred 100% and 88% protection against Y. pestis and anthrax toxin, respectively. In contrast, pDNA-MaF2 conferred only 63% protection against Y. pestis and no protection against anthrax toxin challenge. pDNA-MaF2-prime MaF2-boost induced 75% protection against Y. pestis and 25% protection against anthrax toxin. Protection was increased by the molecular adjuvant CARDif. In conclusion, MaF2 is a promising multi-antigen vaccine candidate against anthrax and plague that warrants further investigation.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85071788792&doi=10.1371%2fjournal.pntd.0007644&partnerID=40&md5=f8fb986bb0da3ffffbc32e46b7e35bfb; http://hdl.handle.net/10713/10857
- Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
- Authors: Albrecht MT, Eyles JE, Baillie LW, Keane-Myers AM
- Issue date: 2012 Aug
- A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
- Authors: Tao P, Mahalingam M, Zhu J, Moayeri M, Sha J, Lawrence WS, Leppla SH, Chopra AK, Rao VB
- Issue date: 2018 Oct 16
- Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
- Authors: Jia Q, Bowen R, Dillon BJ, Masleša-Galić S, Chang BT, Kaidi AC, Horwitz MA
- Issue date: 2018 May 3
- Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
- Authors: Gupta A, Narayan B, Kumar S, Verma SK
- Issue date: 2020
- Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
- Authors: Arnaboldi PM, Sambir M, D'Arco C, Peters LA, Seegers JF, Mayer L, McCormick AA, Dattwyler RJ
- Issue date: 2016 Nov 11